When Biogen announced the deal, the company said it expected a “significant portion” of Apellis staffers would stay on board. (No-Mad/iStock/Getty Images Plus) Biogen isn’t wasting any time ...

Moderna has unveiled its first in vivo CAR-T program. Building on other groups’ ex vivo CAR-T data, the company plans to start clinical development of an off-the-shelf autoimmune disease prospect, ...

The company faces a long road ahead if it hopes to stand out in the crowded obesity development scene, and iBio’s significant change in course in recent years could heap further scrutiny on the ...

The FDA has sent an End of Enforcement notice to consumer wearable device company Whoop, putting a formal end to the agency’s ...

Passage Bio, the Philadelphia-based gene therapy outfit that launched a strategic review earlier this year after tough feedback from the FDA, has found an exit in an ...

Irish CRO giant Icon this week made Microsoft its technology partner as the organization advances its plan to increase investment in AI over the next three years. | Irish CRO giant Icon this week made ...

The trial is expected to begin in the Democratic Republic of Congo next week. (iStock / Getty Images Plus) As health officials grapple with a fast-moving outbreak of the Bundibugyo ebolavirus in the ...

Abbott has become the latest company to team up with Alzheimer’s disease blood test developer ALZpath. | Abbott has become ...

Omnipod maker Insulet has hired Divakar Ramakrishnan, Ph.D., as its new Chief Research and Development Officer. | Omnipod ...

Novartis is paying $105 million upfront to task Antares Therapeutics with generating small molecules against historically undruggable oncology targets. Antares spun out of Scorpion Therapeutics in ...

Osanni launched three years ago with a $27 million series A and has kept purposefully quiet ever since, founder and CEO ...

When writing a blockbuster movie script, screenplay writers are sure to include all the essential elements of a hit | The ...